Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLOSSUS: Long-term Extension Study of Lunsekimig in COPD
NCT07793409Phase 3Enrolling by invitation
- Sponsor
- Sanofi
- Start
- Sep 2026
- Primary completion
- Jul 2031
- Countries
- 3
01
Overview
A Phase 3 trial of lunsekimig in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Sep 2026; status: enrolling by invitation.
02
Drugs
lunsekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07793409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793409.